Lusaris launches with $60 million
C&EN Global Enterprise – November 07, 2022
Source: OpenAlex
Summary
Lusaris Therapeutics has secured $60 million in Series A financing to create innovative treatments for severe neuropsychiatric and neurological conditions. Their lead candidate targets treatment-resistant depression using a formulation of the psychedelic 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) delivered as a dissolvable tablet under the tongue. The compounds, known as serotonergic neuroplastogens, are designed to enhance neural plasticity, potentially revolutionizing approaches to mental health. Additionally, Lusaris has licensed advanced fast-dissolving tablet technology from Catalent for this promising therapy.
Abstract
Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditions. The start-up says the type of compounds it is developing, serotonergic neuroplastogens, are able to induce favorable neural plasticity. Its lead candidate, for treatment-resistant depression, is a formulation of the psychedelic 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) that is administered as a dissolvable tablet under the tongue. The firm has exclusively licensed fast-dissolving tablet technology from Catalent for the lead candidate.